CN110366427A - 一种预防和治疗病理性肾组织损伤的方法 - Google Patents

一种预防和治疗病理性肾组织损伤的方法 Download PDF

Info

Publication number
CN110366427A
CN110366427A CN201780078167.1A CN201780078167A CN110366427A CN 110366427 A CN110366427 A CN 110366427A CN 201780078167 A CN201780078167 A CN 201780078167A CN 110366427 A CN110366427 A CN 110366427A
Authority
CN
China
Prior art keywords
plasminogen
subject
damage
renal
renal tissues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078167.1A
Other languages
English (en)
Chinese (zh)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tailunji International Co ltd
Original Assignee
Tailunji International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tailunji International Co ltd filed Critical Tailunji International Co ltd
Publication of CN110366427A publication Critical patent/CN110366427A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780078167.1A 2016-12-15 2017-06-19 一种预防和治疗病理性肾组织损伤的方法 Pending CN110366427A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2016110174 2016-12-15
CNPCT/CN2016/110174 2016-12-15
CNPCT/CN2016/110169 2016-12-15
CN2016110169 2016-12-15
PCT/CN2017/089060 WO2018107700A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗病理性肾组织损伤的方法

Publications (1)

Publication Number Publication Date
CN110366427A true CN110366427A (zh) 2019-10-22

Family

ID=62557856

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780078167.1A Pending CN110366427A (zh) 2016-12-15 2017-06-19 一种预防和治疗病理性肾组织损伤的方法
CN201780078117.3A Pending CN110167582A (zh) 2016-12-15 2017-06-19 一种预防和治疗药物性肾损伤的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780078117.3A Pending CN110167582A (zh) 2016-12-15 2017-06-19 一种预防和治疗药物性肾损伤的方法

Country Status (7)

Country Link
US (2) US20190328848A1 (https=)
EP (2) EP3556388A4 (https=)
JP (2) JP7242057B2 (https=)
CN (2) CN110366427A (https=)
CA (2) CA3047171A1 (https=)
TW (4) TW202123962A (https=)
WO (3) WO2018107699A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7213552B2 (ja) 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
TWI868051B (zh) 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113456579B (zh) * 2021-07-12 2023-04-25 南开大学 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN101573134A (zh) * 2006-08-28 2009-11-04 欧姆尼治疗有限公司 抗感染候选药物
WO2013049697A1 (en) * 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CN87104683A (zh) * 1986-05-15 1988-12-21 埃默里大学 改善血纤维蛋白溶解作用的组合物
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
MXPA04007585A (es) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
JP2006507297A (ja) * 2002-05-13 2006-03-02 チルドレンズ・ホスピタル・ロサンジェルス ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
CA2509170A1 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2005277137A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
JP5736597B2 (ja) * 2009-05-26 2015-06-17 ウニベルシダド・デ・サラマンカ 急性腎不全又は急性腎不全発症リスクのマーカーとしての尿中ｇｍ２活性化タンパク質
KR20120050442A (ko) * 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
EP2661493B1 (en) * 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
HK1221725A1 (zh) * 2013-08-13 2017-06-09 Sanofi 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
PL3109320T3 (pl) * 2014-02-21 2019-08-30 Astellas Pharma Inc. Nowe przeciwciało anty-ludzki PAI-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN101573134A (zh) * 2006-08-28 2009-11-04 欧姆尼治疗有限公司 抗感染候选药物
WO2013049697A1 (en) * 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. RICHARD KITCHING 等: "Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic Glomerulonephritis", 《J.EXP.MED》 *
ELIZABETH J FISHER等: "Displacement of Tissue Bound Plasminogen by Glucose: A Possible Mechanism in the Pathogenesis of Diabetic Nephropathy", 《ENDOCRINOLOGY AND METABOLISM》 *
庞新路，等: "《现代肾脏病学理论与应用》", 30 June 2013 *
张颖玮，等: "《肾脏病学现代基础与临床》", 30 April 2009 *
袁发焕，等: "《实用肾脏病临床诊疗学》", 30 June 2016 *

Also Published As

Publication number Publication date
JP2020502135A (ja) 2020-01-23
WO2018107695A1 (zh) 2018-06-21
US20190328848A1 (en) 2019-10-31
JP7182793B2 (ja) 2022-12-05
JP7242057B2 (ja) 2023-03-20
WO2018107699A1 (zh) 2018-06-21
TWI642441B (zh) 2018-12-01
EP3556386A1 (en) 2019-10-23
CA3047171A1 (en) 2018-06-21
CN110167582A (zh) 2019-08-23
TW201822797A (zh) 2018-07-01
EP3556388A1 (en) 2019-10-23
CA3047170A1 (en) 2018-06-21
JP2020502134A (ja) 2020-01-23
EP3556388A4 (en) 2020-07-08
WO2018107700A1 (zh) 2018-06-21
EP3556386A4 (en) 2020-07-08
TW201822793A (zh) 2018-07-01
TW201822794A (zh) 2018-07-01
US20190343930A1 (en) 2019-11-14
TW202123962A (zh) 2021-07-01
TWI661838B (zh) 2019-06-11

Similar Documents

Publication Publication Date Title
Luo et al. The role of autophagy in steroid necrosis of the femoral head: a comprehensive research review
Banerjee et al. Management of heart failure patient with CKD
CN110366427A (zh) 一种预防和治疗病理性肾组织损伤的方法
CN110114082A (zh) 一种预防和治疗脂肪代谢紊乱及其相关病症的方法
JP2021504423A5 (https=)
CN110114081A (zh) 一种改善心脏病变的方法
CN110114080A (zh) 一种预防和治疗皮肤纤维化的方法
JP2020510043A5 (https=)
Heine et al. Ten tips to manage oral anticoagulation in hemodialysis patients with atrial fibrillation
Al-Hijji et al. Revascularization for left main and multivessel coronary artery disease: current status and future prospects after the EXCEL and NOBLE trials
Zhang et al. Highly Efficient Intrastromal Dual-Drug Delivery by a Dissolving Bilayer Microneedle for Synergistic Therapy against Corneal Neovascularization
Gerstein et al. Left ventricle thrombus after tranexamic acid for spine surgery in an HIV-positive patient
Rekik et al. ST elevation myocardial infarction with no structural lesions after a wasp sting
Littlefield et al. A reappraisal of the pharmacologic management of gastrointestinal bleeding in patients with continuous flow left ventricular assist devices
Antonescu et al. An unusual case of bilateral upper extremity ischemia caused by forearm vessel fibromuscular dysplasia
RU2546007C2 (ru) Способ лечения ишемии нижних конечностей
Sanford et al. Acute takotsubo cardiomyopathy during elective hernia repair in a patient with previously resected pheochromocytoma
Moreno et al. Editorial [Special Issue on Atherosclerosis Executive Editors: Pedro R. Moreno, Javier Sanz and Valentin Fuster]
US20070049579A1 (en) Medicament having neovascularization promoting action
Amran et al. Adjunctive Mesenchymal Stem Cell Secretome Therapy for a Chronic Hard to Heal Wound in a Patient with Multiple Comorbids: A Case Report. Medical Research Archives,[online] 13 (12)
Monopoli et al. Acute myocardial infarction with occlusion of all three main epicardial coronary arteries: when Mother Nature takes care more than physicians
Van Le et al. Bilateral renal artery thromboembolism during thrombolytic therapy for Embolism-Induced acute limb ischemia
Gulati et al. Hyphema: A Rare Complication of Periprocedural Antiplatelets and Anticoagulants Following Percutaneous Coronary Intervention
Guevara et al. Combined Oral Contraceptives Related Myocardial Infarction, a Risk Factor to Bear in Mind.
Kaesemeyer “CLEAR ADVANTAGE” FROM TARGETING INFLAMMATION RISK OVER LDL RISK

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination